BGI Genomics Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 3.62%

BGI Genomics Co Ltd (300676) has an Asset Resilience Ratio of 3.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of BGI Genomics Co Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥411.01 Million

≈ $60.14 Million USD Cash + Short-term Investments

Total Assets

CN¥11.35 Billion

≈ $1.66 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how BGI Genomics Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is BGI Genomics Co Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down BGI Genomics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 300676 long-term investments to assets to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥411.01 Million	3.62%
Total Liquid Assets	CN¥411.01 Million	3.62%

Asset Resilience Insights

Limited Liquidity: BGI Genomics Co Ltd maintains only 3.62% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

BGI Genomics Co Ltd Industry Peers by Asset Resilience Ratio

Compare BGI Genomics Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Lonza Group AG SW:LONN	Diagnostics & Research	3.04%
Diagnósticos da América S.A SA:DASA3	Diagnostics & Research	10.42%
Shanghai Rendu Biotechnology Co. Ltd. A SHG:688193	Diagnostics & Research	70.50%
Healius Ltd AU:HLS	Diagnostics & Research	0.06%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%
SCOPE FLUIDICS SA ZY-10 F:S84	Diagnostics & Research	32.55%
Avricore Health Inc V:AVCR	Diagnostics & Research	1.71%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%

Annual Asset Resilience Ratio for BGI Genomics Co Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for BGI Genomics Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	4.19%	CN¥492.42 Million ≈ $72.06 Million	CN¥11.75 Billion ≈ $1.72 Billion	+1.20pp
2024-12-31	2.99%	CN¥375.12 Million ≈ $54.89 Million	CN¥12.54 Billion ≈ $1.84 Billion	-2.54pp
2023-12-31	5.54%	CN¥753.58 Million ≈ $110.27 Million	CN¥13.61 Billion ≈ $1.99 Billion	-3.03pp
2022-12-31	8.56%	CN¥1.23 Billion ≈ $180.27 Million	CN¥14.39 Billion ≈ $2.10 Billion	-5.81pp
2021-12-31	14.38%	CN¥2.05 Billion ≈ $299.84 Million	CN¥14.25 Billion ≈ $2.09 Billion	+6.30pp
2019-12-31	8.07%	CN¥482.22 Million ≈ $70.56 Million	CN¥5.97 Billion ≈ $874.29 Million	-0.82pp
2018-12-31	8.89%	CN¥456.23 Million ≈ $66.76 Million	CN¥5.13 Billion ≈ $751.29 Million	-25.46pp
2017-12-31	34.34%	CN¥1.76 Billion ≈ $256.90 Million	CN¥5.11 Billion ≈ $748.02 Million	-3.69pp
2016-12-31	38.03%	CN¥1.61 Billion ≈ $235.43 Million	CN¥4.23 Billion ≈ $619.00 Million	-9.52pp
2015-12-31	47.56%	CN¥1.86 Billion ≈ $272.16 Million	CN¥3.91 Billion ≈ $572.28 Million	--

pp = percentage points

About BGI Genomics Co Ltd

SHE:300676 China Diagnostics & Research

Market Cap

$2.26 Billion

CN¥15.43 Billion CNY

Market Cap Rank

#5818 Global

#1091 in China

Share Price

CN¥36.88

Change (1 day)

+0.05%

52-Week Range

CN¥32.88 - CN¥59.25

All Time High

CN¥248.01